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1 The aims of the study 
 
Heat shock proteins (Hsps) represent major immunodominant antigens in a wide 
spectrum of microbial pathogens and immune reactivity against different members of HSP 
families accompanies many infectious diseases. Known role of Hsps in antigen presentation 
could also suggest their potential role in the alloreactive process that leads to acute graft 
versus host disease (GvHD). Sequence homology and cross-reactivity between microbial 
and human Hsps led to the concept that Hsps might be involved in the etiopathogenesis of 
autoimmune diseases such as juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA). 
The major groups of molecular chaperones have been implicated in cancer development as 
well and stress-inducible Hsp70 was found to be present on the plasma membrane of tumour 
cells but not on the corresponding normal tissues. 
On the basis of previous observations we focused our study on the role of Hsps, namely 
Hsp60 and Hsp70, in the pathogenesis of leukaemia, graft versus host disease, juvenile 
idiopathic arthritis and rheumatoid arthritis. 
 
1.1. Investigation of peripheral blood mononuclear cell responses to heat 
shock proteins and their derived synthetic peptides in patients 
undergoing stem cell transplantation and in patients suffering from 
juvenile idiopathic arthritis 
We studied peripheral blood mononuclear cell (PBMC) responses to recombinant human 
Hsp60 (rh-Hsp60), Mycobacterium bovis Hsp65 (M. bovis Hsp65) and recombinant human 
Hsp70 (rh-Hsp70) in relation to acute GvHD and infection in paediatric patients with various 
lympho-hemopoietic malignancies as well as non-malignant disorders subjected to stem cell 
transplantation (SCT). JIA patients were screened for PBMC responses to rh-Hsp60, M. 
bovis Hsp65 and rh-Hsp70 and their derived peptides. Cell responses were measured after 
the incorporation of 3H-thymidin and were expressed as stimulation indexes (SI). 
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1.2. Analysis of cell surface and relative gene expression of Hsp70 in 
leukaemia and RA patients 
Stress-inducible Hsp70 cell surface and mRNA expression was studied in human 
leukaemia cell lines (K562, Jurkat, CCRF-CEM) during several passages of in vitro culture by 
using flow cytometry and real-time quantitative reverse-transcriptase polymerase chain 
reaction (RT-PCR).  
Next goal of the study was to determine cell surface and mRNA expression of stress-
inducible Hsp70 in synovial cells derived from synovial tissue of RA patients who underwent 
synovectomy. Simultaneously, Hsp70 expression was studied in autologous skin dermis 
gained simultaneously from operation wound and peripheral blood leukocytes of RA patients 
and healthy controls. 
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2 Methods 
 
Overall 7 methods were used in the studies related to the topic of the dissertation thesis. The 
methods are described in details in the publications. 
 
1. Cell proliferation assay with 3H-thymidine incorporation 
2. Mixed lymphocyte culture assay 
3. Solid phase method of peptide synthesis 
4. Cell cultivation and preparation 
5. Flow cytometry 
6. RNA isolation 
7. Real-time quantitative RT-PCR 
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3 Results and discussion 
 
The results of the presented dissertation study are formed by findings of four papers 
which were accepted for publication in international journals.  
 
3.1. Results to aim 1 
3.1.1. Peripheral blood mononuclear cell responses to heat shock proteins in patients 
undergoing stem cell transplantation 
 
(published in Sedlackova L, Sedlacek P, Hromadnikova I. Peripheral blood mononuclear cell 
responses to heat shock proteins in patients undergoing stem cell transplantation. Pediatr 
Transplantation 2006;10:178-186.) 
 
We studied proliferative responses of PBMC to Hsps (rh-Hsp60, M. bovis Hsp65 and rh-
Hsp70) in relation to anamnestic or actual bacterial and/or fungal infection and GvHD in 34 
patients with malignant and non-malignant diseases indicated to SCT. 37 healthy controls 
were also included in this study. Cell proliferation was measured by 3H-thymidine 
incorporation. The most common method is to calculate SI, which is the stimulated cell mean 
cpm divided by the mean cpm of unstimulated cells. Phytohemagglutinin (PHA) was used as 
a control of the stimulation ability.  
 
3.1.1.1. Proliferative responses to Hsps in relation to anamnestic or actual infection 
 
Only a cohort of patients before SCT with responsiveness to PHA (SI > 40) was chosen 
for the analysis to exclude immunocompromised patients not yet recovered from the previous 
chemotherapy. 
PBMC from patients with anamnestic or actual infection showed higher proliferative 
response to stimulation with rh-Hsp60 and M. bovis Hsp65 when compared with patients 
without infection (P = 0.004, P = 0.007) or healthy controls (P = 0.01, P = 0.01), although 
responses to PHA were not significantly different between the two groups (P = 0.57, P = 
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0.71). However, proliferation responses to rh-Hsp70 did not reach statistical significance 
between these two cohorts (P = 0.20, P = 0.88). When we compared proliferative response 
with PHA (P = 0.28, 0.91), rh-Hsp60 (P = 0.04, 0.02), M. bovis Hsp65 (P = 0.03, 0.02) and 
rh-Hsp70 (P = 0.25, 0.78) between an infectious group and healthy children and/or healthy 
adults only, no statistical difference was found. Strong PBMC responses to rh-Hsp60 and/or 
M. bovis Hsp65 were found in patients who were at present colonized with Escherichia coli (n 
= 1) and Klebsiella pneumoniae (n = 1) or had previously K. pneumoniae infection with 
subsequent sepsis (n = 2). In addition, there was a significantly lower proliferative response 
to rh-Hsp60 (P = 0.01), M. bovis Hsp65 (P = 0.006)  and rh-Hsp70 (P = 0.02) from PBMC 
cells obtained from a cohort of paediatric patients without anamnestic and/or actual infection 
when compared with healthy adults. Interestingly, the response to PHA did not differ 
significantly between these two groups (P = 0.16). When we compare proliferative response 
with PHA (P = 0.45), rh-Hsp60 (P = 0.19), M. bovis Hsp65 (P = 0.57) and rh-Hsp70 (P = 
0.92) between a non-infectious group and healthy children only, no statistical difference was 
found.  
Members of HSP families were shown to be the major antigens of many pathogenic 
organisms and they are known to induce very strong humoral and cellular immune responses 
in numerous infections (Zügel and Kaufmann, 1999). Different Hsp cognate proteins have a 
high degree of sequence homology among various pathogenic or non-pathogenic bacteria 
(Shinnick, 1991), for example, Hsp60 in mycobacteria is homologous to the common antigen 
of Pseudomonas aeruginosa and to Hsp60 of other gram-negative bacteria, including GroEL 
of E. coli (Shinnick et al., 1988; Young et al., 1988). Our findings support various studies 
dealing with immunodominant Hsps in connection with selected pathogens. Cellular and/or 
humoral immune response to 60 kDa Hsps was described in K. pneumoniae (Dominguez-
Lopez et al., 2000; Cancino-Diaz et al., 1998), E. coli (Lamb et al., 1989) and Pseudomonas 
aeruginosa (Shinnick et al., 1988; Young et al., 1988) infected patients. The high response in 
patients with an ongoing infection may be because of the synergistic effect between in vivo 
stimulation and in vitro stimulation with Hsps. 
 
3.1.1.2. Proliferative responses to Hsps in relation to acute GvHD 
 
Initially, PBMC responses against rh-Hsp60, M. bovis Hsp65 and rh-Hsp70 were 
compared in a total cohort of patients with acute GvHD onset involving as well as those 
heavily immunocompromised unable to respond to PHA stimulation (SI = 1–326, median 6) 
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and patients with no sign of GvHD (SI = 12.2–340, median 46) during equal posttransplant 
period (11–96 days, median 29.5). Significantly lower responses for rh-Hsp60 (P = 0.005), M. 
bovis Hsp65 (P = 0.004) and rh-Hsp70 (P = 0.04) as well as for PHA (P = 0.008) were 
detected in a cohort of patients with acute GvHD onset. When only a cohort of GvHD 
patients with responsiveness to PHA (SI > 5) was chosen for the statistical analysis to 
evaluate only responders, no statistical difference for proliferative response to PHA was 
observed (P = 0.37) between these two groups, while proliferative responses to rh-Hsp60 (P 
= 0.003), M. bovis Hsp65 (P = 0.01) and rh-Hsp70 (P = 0.05) remained significantly lower in 
a group of patients with acute GvHD onset. 
Furthermore, responses to Hsps in both cohorts of patients with acute GvHD onset and 
patients with GvHD later re-activation were tested. Comparing these two cohorts no 
significant difference in responses to rh-Hsp60 (P = 0.36), M. bovis Hsp65 (P = 0.25) and rh-
Hsp70 (P = 0.21) was found. As expected, SI for PHA reached higher values in patients with 
GvHD later re-activation (1.3–229, median 50) as distinct from patients with acute GvHD (1–
326, median 6), however, this difference did not reach statistical significance (P = 0.07). 
Similarly, when only patients with responsiveness to PHA (SI > 5) were chosen for the 
statistical analysis from both GvHD cohorts, no statistical difference for proliferative response 
to rh-Hsp60 (P = 0.10), M. bovis Hsp65 (P = 0.14) and rh-Hsp70 (P = 0.86) between these 
two groups was found. 
In this study, when we included only patients with myeloablative preparative regimen 
(Busulphan/Cyclophosphamide, total body irradiation/Etoposide, etc.), we got the same 
statistical results for both cohorts of patients with acute GvHD onset and GvHD re-activation 
as mentioned above. 
Several lines of evidence propose that Hsps play a role in the alloreactive process that 
leads to acute GvHD after transplantation. First, Hsps were described to play a role in MHC-
antigen processing (Melnick and Argon, 1995). They have been demonstrated to form Hsp-
peptide complexes that can initiate antigen-specific cytotoxic T-cell responses (Arnold et al., 
1995). These Hsp-chaperoned peptides can be taken up by antigen presenting cells (APCs) 
before being represented on MHC class I molecules (Suto and Srivastava, 1995). In addition, 
Hsp70 may enhance the presentation of antigenic determinants including the minor 
histocompatibility antigens, and promote acute GvHD. Furthermore, Jarvis et al. (Jarvis et al., 
2003) found increased expression of inducible Hsp70 in the skin explant biopsy specimens 
significantly associated with clinical acute GvHD grades II–IV irrespective of GvHD 
prophylaxis. They suggested that this dramatic induction of Hsp70 in graft versus host 
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reaction might be a result of a protective response in an attempt to refold damaged 
polypeptides which is correlated with Hsps’s known function of protein folding and repair.  
We observed predictable values of SI for PHA after SCT, which correlated with clinical 
findings, found to be higher in patients with less intensive depression of immunity (type of 
conditioning, lower dose of drugs to prevent GVHD, etc.) (D’Andrea et al.,1986). We 
presume that lower Hsps stimulations in acute GvHD patients in comparison to patients with 
no sign of GvHD can be explained neither by immunosuppression induced by GvHD 
treatment nor by delayed reconstitution of immunity from grafts. However, it may be 
explained by Van Eden et al. (Van Eden et al., 1998) hypothesis how Hsps could control the 
balance of T-cell regulation.  
Peripheral T-cell responses to self-Hsp are abundant as self-Hsp specific T cells escape 
from negative thymic selection and low-level expression of self-Hsp epitopes on non-
professional APCs leads to the induction of peripheral tolerance. Inflammatory processes, 
including those resulting from acute GvHD, will lead to stress-induced upregulation of Hsp 
synthesis at the site of inflammation, which was also confirmed by Jarvis et al. (Jarvis et al., 
2003). The upregulated Hsps will attract the peripherally tolerized T cells to the site of 
inflammation, where the self-Hsp epitopes will trigger a regulatory or suppressive T-cell 
response via IL-4, IL-10, TGF-β cytokine production (Van Eden et al., 1998). Such a 
phenomenon was described in children with JIA – TH1-type response mediated systemic 
inflammatory disease. T-cell proliferative responses to Hsp60 were present exclusively in 
patients with spontaneously remitting oligoarticular forms of the disease but not in patients 
with progressive (polyarticular or systemic) forms of the disease (De Graeff-Meeder et al., 
1995; Prakken et al., 1996). Such responses showed a pattern of fluctuation that suggested 
that they coincided with the development of remission, i.e. with disease suppression. 
Analysis of T cells in these patients revealed the production of IL-4 and TGF-β, and an 
overexpression of CD30 upon activation with Hsp60, indicating a TH2-type response. 
Reviewing the pathophysiology of acute GvHD, donor T cells become activated by host 
alloantigens, release TH1 cytokines, IL-2 and IFN-γ, which activates macrophages and NK 
cells. Activated macrophages and NK cells can then be triggered by gut bacteria and by 
infections to release large quantities of inflammatory cytokines and active nitrogen 
intermediates, a “cytokine storm“, mediating tissue injury. Cell damage from preparative 
regimens cause as well as transient release of inflammatory cytokines, such as IL-1 and 
TNF-α, that increases the immunogenicity of host APCs (Hakim and Mackall, 1997).  
Similarly, we hypothesize that lower Hsps stimulations in a cohort of patients with acute 
GvHD onset and GvHD later re-activation when comparing with a cohort of patients without 
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GvHD might indicate the predominance of host-reactive donor TH1 cell population and the 
lack and/or insufficient TH2 and TH3–type regulatory response resulting in local host tissue 
damage in the gut, liver and skin. In conclusion, we hypothesize that increased Hsp-specific 
stimulation may reflect the presence of protecting regulatory T cells preventing the 
development of TH1-mediated diseases, involving acute GvHD. 
 
3.1.1.3. Proliferative responses in cultures after antigenic and allogeneic stimulation 
 
In this part of study we determined the proliferative responses to individual antigens and 
allogeneic stimuli and wished to find whether Hsps (rh-Hsp60, M. bovis Hsp65 and rh-Hsp70) 
are able to stimulate alloreactive lymphocytes. PBMC from HLA mismatched healthy 
unrelated individuals were cultured with autologous and allogeneic cells with or without PHA 
and various Hsps. The autologous stimuli induced low levels and the allogeneic stimuli high 
levels of proliferation (SI = 15.5–56.2) as expected. PHA induced maximal proliferation in 
both allogeneic (84 922–86 444 cpm) and autologous (79 846–95 333 cpm) arrangements. 
However, Hsps stimulated allogeneic system more strongly than autologous system. 2.5–
24.4 (rh-Hsp60), 5.2– 35.3 (M. bovis Hsp65) and 1.8–11.3 (rh-Hsp70) fold cpm values were 
demonstrated in allogeneic cultures when compared with the cpm from cultures of 
autologous cells.  
In other words, both autologous and allogeneic mixed lymphocyte cultures induced 
proliferation when appropriate antigen was added to the cell culture, however, significantly 
higher proliferative response was observed in allogeneic system. This may be explained by 
the amplification of T-cell and NK-cell activation because of the synergistic effect of HLA 
class II incompatibility between the unrelated individuals and in vitro Hsp stimulation. 
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3.1.2. Peripheral blood mononuclear cell responses to heat shock proteins and its 
derived synthetic peptides in juvenile idiopathic arthritis patients 
 
(published in Sedlackova L, Velek J, Vavrincova P, Hromadnikova I. Peripheral blood 
mononuclear cell responses to heat shock proteins and its derived synthetic peptides in 
juvenile idiopathic arthritis patients. Inflamm Res 2006;55:153-9.) 
 
The aim of our study was to investigate PBMC proliferative responses to Hsps and Hsp-
derived synthetic peptides in a cohort of 48 patients with JIA and compare with healthy 
controls (n = 38). Beside Hsps (rh-Hsp60, M. bovis Hsp65 and rh-Hsp70), we tested these 
peptides: human Hsp60 (562–571) peptide, which shares sequence homology with 
cytokeratin (545–554), one of the known RA autoantigens (Jones et al., 1993). Next, we also 
used M. bovis Hsp65 (180-188) peptide, whose observed cross-reactivity with cartilage 
proteoglycan may cause inflammation in the joints and may be involved in the pathogenic 
effector mechanism (De Kleer et al., 2003). Finally, Hsp70 derived N-terminal-extended 14-
mer peptide (TKD, 450–463) was chosen on the basis of described ability to stimulate 
cytolytic and proliferative activity of NK cells equipotently with full-length Hsp70 protein 
(Multhoff et al., 2001). 
We investigated also an association between the proliferative response to Hsp and Hsp-
derived synthetic peptides and clinical characteristics like rheumatoid factor (RF), antinuclear 
antibodies (ANA), HLA B27, the duration and the activity of the disease. PHA was used as a 
control of the stimulation ability in assay using the incorporation of 3H-thymidine. 
 
3.1.2.1. Proliferative responses to Hsps and Hsp-derived synthetic peptides 
 
While PHA stimulation was not significantly different between the cohort of JIA patients 
and healthy controls (P = 0.23), PBMC proliferative responses to rh-Hsp60 (6/43 x 3/38), M. 
bovis Hsp65 (9/47 x 3/36), rh-Hsp70 (8/44 x 2/36) and P180–188 derived from M. bovis 
Hsp65 (9/45 x 1/34) were elevated in a cohort of JIA patients. However, only responses to M. 
bovis Hsp65 reached the statistical significance (P = 0.01). There was no proliferative 
response to P450–463 peptide derived from rh-Hsp70 in JIA patients. These results are 
concordant with initial studies reported by Graeff-Meeder et al. (Graeff-Meeder et al., 1991) 
who described increased proliferative responses to rh-Hsp60 and M. bovis Hsp65. Our data 
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confirmed also the results of Danieli et al. (Danieli et al., 1992) who reported elevated 
responses to P180–188 M. bovis Hsp65 derived peptide in patients with JIA.  
Furthermore, PBMC responses to Hsps and Hsp-derived synthetic peptides were 
compared in various JIA subgroups and healthy individuals. A positive response (SI above 
mean plus 2 SD of healthy controls) to rh-Hsp60 (4/27), M. bovis Hsp65 (6/29), rh-Hsp70 
(6/27), P562–571 human Hsp60 (6/29) and P180–188 M. bovis Hsp65 (7/29) derived 
peptides was observed predominantly in patients with polyarthritis. However, only responses 
to rh-Hsp60 (P = 0.03), M. bovis Hsp65 (P = 0.01) and P562–571 human Hsp60 derived 
peptide (P = 0.02) were significantly above those of healthy controls. 
P545–554 cytokeratin derived peptide synthesized on the basis of examination of the 
entire sequence of human Hsp60 for similarities with some known autoantigens (Jones et al., 
1993) showed no proliferative responses in JIA patients. However, P562–571 sequence of 
human Hsp60 showed significant stimulation in polyarthritis in contrast to P545–554 
cytokeratin derived peptide even though they share the sequence homology with only one 
amino acid interchange. We found no PBMC proliferative responses to P450–463 human 
Hsp70 derived peptide in JIA patients, which was described to stimulate the cytolytic and 
proliferative activity of NK cells equally to the full-length Hsp70 protein (Multhoff et al., 2001). 
This observation is consistent with findings of Multhoff et al. (Multhoff et al., 2001) who 
described the absence of T cell response against the peptide plus low-dose IL-2 in healthy 
individuals. 
 
3.1.2.2. Influence of clinical characteristics on proliferative responses to Hsps and 
Hsp-derived synthetic peptides 
 
The possible influence of clinical characteristics of JIA patients was also analysed. 
Patients were subdivided into further groups: RF+ vs. RF-, ANA+ vs. ANA-, HLA B27+ vs. 
HLA B27-, patients in remission (with or without the therapy) vs. patients with active disease 
and patients with early (0–2 years) and established disease (patients with duration of the 
disease over 2 years). No relationship was found between the RF, ANA and HLA B27 
presence and the Hsp and Hsp-derived synthetic peptide proliferation in a cohort of JIA 
patients. 
Initially, no relation was found between responses both to Hsps and Hsp-derived 
synthetic peptides and disease activity when we compared patients in remission with those 
with active disease. However, when we evaluated the data besides depending on the 
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therapy in the remission group, we found significantly higher proliferative response to rh-
Hsp60 (P = 0.03), M. bovis Hsp65 (P = 0.03), rh-Hsp70 (P = 0.02) and P180–188 derived 
from M. bovis Hsp65 (P = 0.004) in a cohort of patients without the therapy. Significantly 
higher proliferative response to P180–188 derived from M. bovis Hsp65 (P = 0.007) was also 
observed in remission group without the therapy when compared with active disease group. 
Positive proliferative responses to all Hsps and P562– 571 human Hsp60 and P180–188 M. 
bovis Hsp65 derived peptides were observed exclusively in patients with established disease 
when compared with patients with early disease. However, only proliferative response to 
P180–188 derived from M. bovis Hsp65 reached the statistical significance (P = 0.04). 
We have shown no positive proliferative responses to any Hsps and Hsp-derived peptide 
in a cohort of patients with early onset of polyarthritis, systemic disease and HLA B27 
negative oligoarthritis, none of them achieved the remission. These data correspond with 
those of De Graeff-Meeder et al. (De Graeff-Meeder et al., 1995) and Prakken et al. (Prakken 
et al., 1996), who reported significant in vitro T-cell responses to human Hsp60 within 4 
weeks to 3 months after the onset of HLA B27 negative oligoarticular JIA with favourable 
outcome associated with immunoregulatory control leading often to remission when the 
previous positive responses to rh-Hsp60 were lost. At the early stage of arthritis no highly 
specific responses for polyarthricular and systemic onset forms of JIA were observed 
(Prakken et al., 1996). 
However, it looks like that the situation in patients with later stages of JIA disease is 
completely different, since we observed positive proliferative responses to all Hsps and 
P562–571 human Hsp60 and P180–188 M. bovis Hsp65 derived peptides exclusively in 
patients with established disease. These data can be supported by De Kleer et al. (De Kleer 
et al., 2003) who found elevated response towards Hsp60 in polyarticular and systemic 
disease and by Prakken et al. (Prakken et al., 2002) who described responses towards self-
Hsp60 in polyarticular JIA at later stages of disease activity.  
It was suggested that human Hsp60-specific T cells have regulatory function and 
contribute to disease remission in oligoarticular JIA patients (De Kleer et al., 2003). De Kleer 
et al. (De Kleer et al., 2003) also speculate that T cell responses against human Hsp60 in 
polyarticular JIA patients are qualitatively different; they appear later in the course of the 
disease, probably through bystander activation, and show no regulatory features. We 
hypothesize that this observation may regard not only T cell responses to rh-Hsp60 but also 
to M. bovis Hsp65, rh-Hsp70, P180–188 M. bovis Hsp65 and P562–571 human Hsp60 
derived peptides as we showed in several patients with established polyarticular JIA in our 
studied cohort. 
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3.2. Results to aim 2 
3.2.1. Cell surface and relative gene expression of Hsp70 in human leukaemia cell 
lines 
 
(published in Hromadnikova I, Sedlackova L. Analysis of cell surface and relative gene 
expression of heat shock protein 70 in human leukemia cell lines. Leuk Lymphoma 
2008;49(3): 570 – 576.) 
 
The goal of this part of study was to determine cell surface and mRNA expression of 
stress-inducible Hsp70 on leukaemia cell lines derived from patients with chronic myeloid 
leukaemia (Bcr-Abl positive K562 cells) and T-cell acute lymphoblastic leukaemia (Bcr-Abl 
negative Jurkat and CCRF-CEM cells). Hsp70 cell surface and mRNA expression was 
studied in K562, Jurkat and CCRF-CEM human leukaemia cell lines during several passages 
of in vitro culture by using flow cytometry and real-time quantitative RT-PCR. 
Phenotypic analysis revealed that Hsp70 positivity on the plasma membrane of K562 
cell line appeared approximately around the 61st day of the culture and reached the highest 
value on the day 72 (46.1%). Cell surface expression did not reach the cut-off from the 
beginning till the 42nd day of culture. A cut-off value for Hsp70 of 10% was chosen based on 
the results from previous screening of normal cells and tissues (peripheral blood 
lymphocytes and skin fibroblasts) by flow cytometry (Farkas et al., 2003; Nguyen et al., 
2006). However, Jurkat and CCRF-CEM cell lines were Hsp70 membrane positive 
continuously from the beginning till the end of the culture and consequently monitored in the 
shorter cultivation period. The decrease of cell surface expression in these cell lines was 
observed with ongoing time of the culture.  To compare cell surface with relative Hsp70 gene 
expression in leukaemia cell lines, RNA isolation was carried out at the same day of culture 
as flow cytometry acquisition. We found that mRNA expression in K562 cells was 9.88-fold 
higher in average when compared with healthy control. However, Hsp70 mRNA expression 
in Jurkat and CCRF-CEM cell lines was 0.47-fold and 0.62-fold lower in comparison with 
healthy control. Spearman’s rank correlation was used to discover the strength of a link 
between two variables – Hsp70 cell surface and relative gene expression. Statistically 
significant strong negative correlation was found in case of Jurkat cell line. Weak positive 
correlation was observed in K562 and CCRF-CEM cell lines, however, the data did not reach 
the statistical significance. 
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The finding of positive cell surface Hsp70 expression in all of the leukaemia cell lines is 
in concordance with previous results describing frequent expression on the plasma 
membranes of tumour cells but not on normal cells (Multhoff et al., 1995; Shin et al., 2003; 
Gehrmann et al., 2002; Ferrarini et al., 1992; Hantschel et al., 2000; Gehrmann et al., 2003). 
The difference in cell surface Hsp70 expression among studied cell lines is probably due to 
the distinct types of leukaemia. Similar to other investigators we observed decreased 
membrane-bound Hsp70 expression in senescent and late-passage cells (Liu et al., 1989; 
Luce and Cristofalo, 1992; Effros et al., 1994). 
We found increased mRNA expression only in K562 cells when compared with healthy 
control, though we observed positive cell surface Hsp70 expression in all cell lines. Hsp70 
mRNA expression in Jurkat and CCRF-CEM cells was even lower in most analyses when 
compared with healthy control. We presume that highly increased cell surface expression 
together with non-elevated mRNA expression in Jurkat and CCRF-CEM cell lines could be 
clarified with the self-limiting control mechanism of overexpressed Hsp70 protein. It was 
showed that activated heat shock factor (HSF) associates with Hsp70 and suggested that 
Hsp70 may negatively regulate the activation of HSF (Abravaya et al., 1992). Ding et al.’s 
(Ding et al., 1998) data also suggested that overexpression of Hsp70 led to decreased 
Hsp70 gene transcription. The accumulated evidence suggested the presence of a negative 
feedback mechanism that prevented overproduction of Hsp70. Overexpressed Hsp70 was 
also found to inhibit the activation of HSF1, by activating protein phosphatase and inhibiting 
protein kinase C activity (Ding et al., 1998; Mosser et al., 1993; Kim et al., 1995). Other study 
previously showed that an increase in the degradation of Hsp70 mRNA was parallel to the 
accumulation of Hsp70. Later Hsp70 was found to bind to Hsp70 mRNA after stress and this 
interaction was suggested to be part of a self-limiting mechanism to reduce Hsp70 
production (Balakrishnan and de Maio 2006). It seems that the cell surface expression in 
K562 cells changes according to the changes in mRNA expression during the cell culture. 
We suppose that the level of cell surface Hsp70 expression probably may not be sufficient to 
downregulate the mRNA expression.  
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3.2.2. Analysis of cell surface and relative gene expression of Hsp70 in RA patients 
 
(published in Sedlackova L, Nguyen TTH, Zlacka D, Sosna A, Hromadnikova I. Cell surface 
and relative mRNA expression of heat shock protein 70 in human synovial cells. 
Autoimmunity 2008 (in press)). 
 
Hsp70 cell surface and mRNA expression were studied in human fibroblast-like synovial 
cells, dermal fibroblasts and peripheral blood leukocytes derived from 24 RA patients, who 
underwent synovectomy by using flow cytometric analysis and real-time quantitative RT-
PCR. For comparison, peripheral blood leukocytes of 17 healthy controls were tested. Since 
no control synovial tissues from non-inflammatory joint diseases like traumatic joint diseases 
or degenerative joint disease (osteoarthritis) were available to make comparison to chronic 
inflammatory arthritides (RA), the study was expanded for the data concerning autologous 
dermal fibroblasts derived from the operation wound of patients with RA. 
Consistently with our previous studies (Nguyen et al., 2006; Hromadnikova et al., 2008) 
Hsp70 membrane positivity was detected on fibroblast-like synovial cells in 13 out of 18 RA 
patients (median 16.5%) in contrast to autologous or healthy control peripheral blood 
lymphocytes (RA patients: median 2.9%; healthy controls: median 4.5%) and/or autologous 
dermal fibroblasts (median 4.3%), which showed in most cases no Hsp70 membrane 
expression. Increased Hsp70 expression on fibroblast-like synovial cells when compared 
with autologous and/or healthy control peripheral blood lymphocytes (P = 0.002, P = 0.002) 
as well as autologous dermal fibroblasts (P < 0.001) was statistically significant. Healthy 
control peripheral blood lymphocytes were used as a negative control for Hsp70 cell surface 
expression studies. We observed strong Hsp70 cell surface expression on monocytes in all 
tested patients (median 58.1%) and healthy controls (median 47.5%) even if not statistically 
significant (P = 0.52). A significantly higher Hsp70 membrane expression was found on 
granulocytes of healthy controls (median 6.4%) when compared with granulocytes of RA 
patients (P = 0.005).  
Significantly higher relative Hsp70 gene expression in RA-derived synovial cells (median 
1.70) was observed when compared with autologous peripheral blood leukocytes (median 
0.68, P < 0.001). However, we found significantly lower relative gene expression in 
peripheral blood leukocytes of RA patients in comparison with healthy controls (median 1.64, 
P < 0.001). On the other hand, Hsp70 gene expression compared between RA-derived 
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synovial cells and peripheral blood leukocytes of healthy controls did not reach any statistical 
significance (P = 0.83). Interestingly, we found that Hsp70 gene expression in RA non-
affected skin dermis gained from the operation wound was 3.7-fold higher in average 
(median 8.30) when compared to autologous RA-affected synovial tissue (P < 0.001); 10.1-
fold higher in average when compared to autologous peripheral blood leukocytes (P < 0.001) 
and 4.5-fold higher in average comparing to control peripheral blood leukocytes (P < 0.001).  
Our finding concerning Hsp70 membrane positivity on fibroblast-like synovial cells in RA 
patients was consistent with the data of Schett et al. (Schett et al., 1998), who previously 
reported enhanced cytoplasmic expression of inducible Hsp70 in RA synovial tissue using 
Western blotting, immunohistochemistry and immunofluorescence. However, in another 
study the overexpression of constitutive heat shock cognate 70 (Hsc70) but not inducible 
Hsp70 was detected in RA synovial lining cells using immunochemistry and Western blotting 
(Schick et al., 2004). 
Since many cell surface receptors like CD14, scavenger receptors (CD36, lectin-like 
oxidized low-density lipoprotein receptor (LOX-1), etc.), CD40, α2-macroglobulin/- low-
density lipoprotein receptor (LRP/CD91), Toll-like receptors (TLR-2 and TLR-4) and c-type 
lectins (CD94, etc.) that can bind Hsps (Calderwood et al., 2007) were described, we 
presume that we might detect extracellular Hsp70 bound to these receptors expressed on 
peripheral blood monocytes and granulocytes. To support this hypothesis, significantly higher 
levels of soluble inducible Hsp70 were detected in synovial fluids of RA patients. Further, 
soluble inducible Hsp70 was also detected in sera of RA patients as well as in healthy 
controls (Martin et al., 2003; Hromadnikova et al., 2008).  
Hsp70 is the major stress-inducible Hsp, whose gene expression must be tightly 
regulated. However, the precise mechanism for control of Hsp70 expression has not been 
completely delineated.  
Significantly higher Hsp70 gene expression observed in synovial cells of RA patients 
when compared with autologous peripheral blood leukocytes could support the observation 
of Hsp70 positive cell surface expression on synovial cells derived from RA-affected joints. 
However, the difference in Hsp70 gene expression between RA-derived synovial cells and 
healthy control peripheral blood leukocytes was not observed. We also found significantly 
lower relative gene expression in peripheral blood leukocytes of RA patients in comparison 
with healthy controls. We speculate that this observation might be explained by the 
administration of immunosuppressive therapy in a cohort of RA patients. However, Schett et 
al. (Schett et al., 1998) described that non-steroidal anti-inflammatory drugs triggered only an 
incomplete heat shock response, with HSF1 activation but not Hsp70 induction, whereas 
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steroids and immunosuppressive drugs did not affect the heat shock response at all. 
Interestingly, the highest Hsp70 gene expression was observed in RA non-affected skin 
dermis gained from the operation wound when compared to autologous RA-affected synovial 
tissue, autologous and/or control peripheral blood leukocytes. Skin as a barrier to the 
environment is much more exposed to various external factors, such as heat, UV light, 
microorganism, chemicals, etc., causing mainly apoptosis of epidermal keratinocytes. Some 
of them may affect even the deeper layers containing dermal fibroblasts. Hsp70 expression is 
important as a molecular repair factor that maintains the protective function of the normal 
skin. As a physiological response to potentially harmful environmental stress factors, these 
cells produce higher levels of Hsp70 comparing to the cells of internal organs and tissues 
(Trautinger et al., 1993). We speculate that the Hsp70 expression in skin dermis might be 
intensified also by the shock caused by the disinfection and sterile folio cover of the field of 
the operation, however, dermal fibroblasts were growing from the primary tissue very well in 
most patients. 
We summarise that an increased Hsp70 gene expression in RA-affected synovial tissue 
is followed by Hsp70 cell surface expression on fibroblast-like synovial cells growing from RA 
synovial tissue. Hsp70 may be translocated to the cell surface from the cytosol and/or Hsp70 
released from inflamed synovial tissue may be captured onto the membrane of synovial cells 
from the extracellular space via the CD91 receptor as we have reported recently 
(Hromadnikova et al., 2008). The significance of the Hsp70 presence on the cell surface of 
RA-affected synovial cells remains undefined but may take part in the development of a 
higher resistance to stress-induced apoptosis. 
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4 Conclusion 
 
The importance of Hsps has been established by numerous studies concerning 
infection, inflammation, autoimmune disease and tumour immunity. Our research focused in 
particular on the supposed role of Hsps in pathogenesis of acute GvHD with simultaneous 
study of Hsps responses in actual and/or anamnestic infections. Similar Hsp study was also 
done in the cohort of JIA patients with the expansion for the responses against Hsp-derived 
synthetic peptides. Our another study targeted the cell surface and mRNA expression of 
Hsp70 in leukaemia cell lines and RA-affected synovial tissue. The summarized results are 
listed below. 
 Significantly high proliferative response to rh-Hsp60 as well as M. bovis Hsp65 was 
demonstrated in a cohort of pretransplant patients with anamnestic and/or actual infection 
when compared with a cohort of patients without infection and healthy individuals. Strong 
PBMC responses to Hsps were found in patients who were at present colonized with 
Escherichia coli and Klebsiella pneumoniae or had previously K. pneumoniae infection with 
subsequent sepsis. Our findings support various studies dealing with immunodominant Hsps 
in connection with several pathogens and infectious diseases.  
Although no statistical difference for proliferative response to PHA was observed, PBMC 
responses against all tested Hsps comparing a cohort of patients with acute GvHD and that 
with no sign of GvHD resulted in significantly lower SI for all tested Hsps in patients with 
acute GvHD. Lower stimulation with Hsps during acute GvHD might be explained by the 
stress-induced upregulation of self-Hsps synthesis that might lead to the inhibition of self-
Hsps reactive T-cell response and that it might indicate the predominance of host-reactive 
donor TH1 cell population and the lack and/or insufficient TH2 and TReg response resulting in 
local host tissue damage in the gut, liver and skin. We hypothesize that increased Hsp-
specific stimulation may reflect the presence of protecting regulatory T cells preventing the 
development of TH1-mediated diseases involving acute GvHD. 
 Elevated proliferative response to rh-Hsp60, M. bovis Hsp65 and P562–571 human 
Hsp60 derived peptide was found in patients with JIA polyarthritis. Significantly elevated 
proliferation to P180–188 M. bovis Hsp65 was found in JIA lasting more than 2 years. None 
of the particular clinical characteristics (RF, ANA, HLA B27 and disease activity) seemed to 
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be associated with Hsp or Hsp-derived synthetic peptide proliferative response in the JIA 
cohort.  
 
 Hsp70 was found to be expressed on the cell surface of K562, Jurkat and CCRF-
CEM human leukaemia cell lines during several passages of in vitro culture. Even if all the 
cell lines were positive for cell surface Hsp70 expression, increased mRNA expression was 
observed only in K562 cells when compared with healthy controls. Our observation in this 
study raises the questions about the possible inhibition switch of the gene transcription in 
dependence on the elevation of the protein expression, which could explain the non-elevated 
mRNA expression in Jurkat and CCRF-CEM cell lines. 
 
 Hsp70 gene expression in RA-affected synovial tissue is followed by Hsp70 cell 
surface expression on fibroblast-like synovial cells growing from RA synovial tissue. 
Significantly higher Hsp70 membrane positivity was found on fibroblast-like synovial cells in 
RA patients than on autologous and healthy control peripheral blood lymphocytes and/or 
autologous dermal fibroblasts. We also observed significantly higher Hsp70 gene expression 
in synovial cells of RA patients when compared with autologous peripheral blood leukocytes. 
Interestingly, we found that Hsp70 gene expression in RA non-affected skin dermis gained 
from the operation wound was higher when compared to autologous RA-affected synovial 
tissue. As a physiological response to potentially harmful environmental stress factors, skin 
dermis apparently produces higher levels of Hsp70 comparing to the cells of internal organs 
and tissues. 
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